Document is current
Any future updates will be listed below
-
Authors
Lopez-Estebaranz, Jose L. https://orcid.org/0000-0002-8816-1989
Lopez-Pando, Marta https://orcid.org/0009-0005-4385-5935
Mitsunaga, Keila https://orcid.org/0000-0002-2893-3609
- License Information
-
More Information
Article History
Received: 21 September 2025
Accepted: 11 May 2026
First Online: 3 June 2026
Declarations
:
: No funding was received for the preparation of this article.
: Jose L. Lopez Estebaranz served as a consultant, participated in clinical trials and/or received speaking fees from Almirall, BMS, Janssen, Leo-Pharma, Lilly, AbbVie, Bioderma, Galderma, UCB, Novartis, Pierre-Fabre, Invasix, Isdin, and Incyte.Marta L .Pando has no conflicts of interest that are directly relevant to the content of this article. Keila Mitsunaga received support for travel/meeting participation from Recordati Rare Diseases, Kyowa Kirin, Almirall, Asterasys, Isdin, Cantabria Labs, and Leo Pharma.
: Not applicable.
: Not applicable.
: Not applicable.
: Data are available upon request to the corresponding author.
: Not applicable.
: JLLE was responsible for conceptualization, methodology, data acquisition and analysis, and writing, editing, and revising the manuscript. MLP was responsible for methodology, data acquisition and analysis, and writing, editing, and revising the manuscript. KM was responsible for conceptualization, methodology, data acquisition and analysis, and writing, editing, and revising the manuscript.
